CytoReason’s Post

These days we’re seeing leading venture firms and key strategic partners investing billons of dollars in AI companies focused on improving patient care, drug development, and clinical efficiency. For example, Spring Health recently secured $100 million to develop the company’s AI platform which matches patients with appropriate care providers and treatment plans. Amazon Web Services (AWS) and GE HealthCare are collaborating to leverage AI models to enhance standard of care in the healthcare sector. And in CytoReason's case, NVIDIA, Pfizer, Thermo Fisher Scientific, OurCrowd, and others are investing in our computational models, so we can develop more disease models in more therapeutic areas, address diverse patient populations with molecular and clinical data, and ultimately empower decision-makers with AI tools intended to help them increase the probability of phase 2 success. https://lnkd.in/dBp9FUuQ